Wednesday, July 8, 2026

Drug profile · INN

adenosine

adenosine (ADENOSINE) is a adenosine receptor agonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 3
News articles 0
Drug details — adenosine
US status
approved
Class
Route
INJECTION
Patents
20
Programs
3
Data quality
0.89

Quick answer

adenosine (ADENOSINE) is a adenosine receptor agonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.

Key facts

INN adenosine
Brand ADENOSINE
Mechanism Adenosine receptor agonist
Target Adenosine receptor
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Adenosine receptor agonist

Primary target: Adenosine receptor

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Beclomethasone dipropionate HFA Phase 2 · Teva Pharma · Asthma
  2. 20230223 Phase 1 · Amgen · Gastrointestinal tract, biliary tract, or pancreatic cancers
  3. A Phase 1a/b Study Investigating the Safety for Advanced, or metastatic solid t… Phase 1 · BEONE MEDICINES AUS · Advanced, or metastatic solid tumors with methylthioadenosin

Related & competitor drugs

  1. aminophylline Adenosine receptor antagonist
  2. caffeine citrate Nervous system (N06)
  3. theophylline Phosphodiesterase 4 inhibitor
  4. caffeine Nervous system (N06)
  5. istradefylline Nervous system (N04)
  6. oxtriphylline Phosphodiesterase 3 inhibitor
  1. US 12426594

    Cryoprotective compositions and methods for protection of a surgical site during cryosurgery

    Expires 2045-09-25T00:00:00.000Z

    granted
  2. US 12427151

    Compositions and method of treating cancer

    Expires 2045-09-25T00:00:00.000Z

    granted
  3. US 12427197

    Methods of producing cobalt nanoparticles and hollow metal nanospheres

    Expires 2045-09-25T00:00:00.000Z

    granted
  4. US 12419866

    Compounds and methods for treating an epileptic disorder

    Expires 2045-09-18T00:00:00.000Z

    granted
  5. US 12419811

    Hydrogel drug delivery composition

    Expires 2045-09-18T00:00:00.000Z

    granted
  6. US 12421525

    Conjugates comprising AAVs and CAS9 polypeptides

    Expires 2045-09-18T00:00:00.000Z

    granted
  7. US 12414907

    Peptide having hair growth promoting activity and use thereof

    Expires 2045-09-11T00:00:00.000Z

    granted
  8. US 12415863

    Compositions and methods for treating cancer

    Expires 2045-09-11T00:00:00.000Z

    granted
  9. US 12416008

    Compositions and methods of use for small-molecule regulation of CRISPR-Cas9 activity using RNA aptamers

    Expires 2045-09-11T00:00:00.000Z

    granted
  10. US 12410399

    Compositions and methods for treating retinal diseases

    Expires 2045-09-04T00:00:00.000Z

    granted
  11. US 12403192

    Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease

    Expires 2045-08-28T00:00:00.000Z

    granted
  12. US 12403093

    Methods for production of MSC-derived exosomes

    Expires 2045-08-28T00:00:00.000Z

    granted
  13. US 12398375

    Methods for improved poxvirus yields

    Expires 2045-08-21T00:00:00.000Z

    granted
  14. US 12396949

    Technology for improving properties of lipid nanoparticles using lipids in which cis-unsaturated bonds are substituted with a silicon atom

    Expires 2045-08-21T00:00:00.000Z

    granted
  15. US 12396994

    Compositions for improving physiological function with age

    Expires 2045-08-21T00:00:00.000Z

    granted
  16. US 12391654

    CFTR regulators and methods of use thereof

    Expires 2045-08-14T00:00:00.000Z

    granted
  17. US 12391643

    Substituted amino-thiol and amino-disulfide compounds, and uses thereof

    Expires 2045-08-14T00:00:00.000Z

    granted
  18. US 12390483

    Compounds and methods for treating neurological and cardiovascular conditions

    Expires 2045-08-14T00:00:00.000Z

    granted
  19. US 12383518

    Disulfide-masked pro-chelator compositions and methods of use

    Expires 2045-08-07T00:00:00.000Z

    granted
  20. US 12383655

    Methods of isolating and using descemet's membrane and compositions including isolated descemet's membrane

    Expires 2045-08-07T00:00:00.000Z

    granted

Frequently asked questions

What is adenosine?

adenosine (ADENOSINE) is a adenosine receptor agonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.

What is the brand name for adenosine?

ADENOSINE is a marketed brand name for adenosine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of adenosine?

adenosine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.